姓名 | 職稱 | 持有股份 | 代表法人 |
---|---|---|---|
Zhang,Shi-Zhong | Chairman | 1.29% | |
Zhang,Zi-Ling | Director | 10.18% | EVERSPRING INDUSTRY CO., LTD. |
Huang,Zi-Liang | Director | 1.74% | HUA CHEN SECURITY CO., LTD. |
Zhuang,Ming-Li | Director | 3.14% | DA QING CONSTRUCTION CO., LTD. |
Zhuang,Xiu-Ming | Independent Director | 0.00% | |
Wang,Zhu-Ke | Independent Director | 0.00% | |
Chen,Bei-Wei | Independent Director | 0.00% | |
Lin,Xue-Rong | Independent Director | 0.00% |
項目 | 2025 | 2024 | 2023 |
---|---|---|---|
Operating income | 499,372 | 1,372,701 | 1,157,720 |
Operating cost | 144,290 | 618,944 | 540,391 |
Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
Operating gross profit (loss) | 355,082 | 753,757 | 617,329 |
Unrealized profit (loss) on sales of goods | 51,126 | - | - |
Realized profit (loss) on sales of goods | - | - | - |
Operating gross profit (loss), net | 303,956 | 753,757 | 617,329 |
Operating expenses | 206,122 | 970,952 | 1,850,422 |
Other gain (loss), net | - | - | - |
Operating profit (loss) | 97,834 | -217,195 | -1,233,093 |
Non-operating income and expenses | 6,688 | 104,479 | -45,767 |
Net profit (loss) before tax | 104,522 | -112,716 | -1,278,860 |
Income tax expense (benefits) | 7,493 | 109,673 | 191,207 |
Net profit (loss) of ongoing business for the current period | 97,029 | -222,389 | -1,470,067 |
Profit (loss) of closed units | - | - | - |
Profit (loss) of non-jointly controlled equity before merger | - | - | - |
Net profit (loss) for the current period | 97,029 | -222,389 | -1,470,067 |
Other comprehensive profit (loss), net | -76,392 | 85,867 | 16,038 |
Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
Total comprehensive profit and loss for the current period | 20,637 | -136,522 | -1,454,029 |
Net profit (loss) attributable to owners of parent company | 102,450 | -204,690 | -561,296 |
Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Net profit (loss) attributable to non-controlling interests | -5,421 | -17,699 | -908,771 |
Comprehensive profit (loss) attributable to owners of parent company | 74,771 | -174,729 | -554,889 |
Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
Comprehensive profit (loss) attributable to non-controlling interests | -54,134 | 38,207 | -899,140 |
Basic earnings per share (yuan) | 0 | -1 | -4 |
項目 | 2025 | 2024 | 2023 |
---|---|---|---|
Net cash inflow (outflow) from operating activities | -28,958 | 37,919 | -503,517 |
Net cash inflows (outflows) from investing activities | -374,749 | 903,302 | 497,660 |
Net cash inflow (outflow) from financing activities | -6,494 | -1,773,172 | 193,152 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -707 | -3,262 | -5,002 |
Increase (decrease) in cash and cash equivalents in the current period | -410,908 | -835,213 | 182,293 |
Beginning balance of cash and cash equivalents | 1,387,713 | 2,222,926 | 2,040,633 |
Ending balance of cash and cash equivalents | 976,805 | 1,387,713 | 2,222,926 |
項目 | 2025 | 2024 | 2023 |
---|---|---|---|
Current asset | 3,709,505 | 3,661,148 | 5,708,037 |
Non-current asset | 2,908,549 | 3,049,345 | 2,819,208 |
Total asset | 6,618,054 | 6,710,493 | 8,527,245 |
Current liability | 790,840 | 925,220 | 2,779,891 |
Non-current liability | 731,733 | 747,214 | 750,225 |
Total liability | 1,522,573 | 1,672,434 | 3,530,116 |
share capital | 1,393,068 | 1,393,068 | 1,394,748 |
Equity - secruity token | - | - | - |
capital reserve | 566,460 | 536,791 | 968,142 |
retained earning | -250,212 | -352,662 | -747,509 |
Other equity | -22,986 | 4,693 | -23,738 |
Treasury stock | - | - | - |
Total equity attributable to owners of parent company | 1,686,330 | 1,581,890 | 1,591,643 |
Equity attributable to former owner of business combination under common control | - | - | - |
Equity attributable to non-controlling interest before business merger under common control | - | - | - |
Non-controlling interests | 3,409,151 | 3,456,169 | 3,405,486 |
Total Equity | 5,095,481 | 5,038,059 | 4,997,129 |
Share capital awaiting retirement (unit: share) | - | 0 | 200,000 |
Issued shares of advance equity (unit: shares) | 0 | 0 | 83,500 |
Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
Net asset value per share | 12 | 11 | 11 |
標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
---|---|---|---|---|
HLA-B27定型試劑套組單價合約 | 國立臺灣大學醫學院附設醫院 | 106/04/25 | 276480.0 | 是 |
HLA-B27定型試劑套組 | 國立臺灣大學醫學院附設醫院 | 106/01/06 | 115200.0 | 是 |
HLA-B27定型試劑套組 | 國立臺灣大學醫學院附設醫院 | 105/05/18 | 115200.0 | 是 |
HLA-B27定型試劑套組 | 國立臺灣大學醫學院附設醫院 | 103/07/09 | 890112.0 | 是 |
HLA定序分型試劑套組(附儀器) | 國立臺灣大學醫學院附設醫院 | 103/01/06 | 否 | |
HLA-B27定型試劑套組 | 國立臺灣大學醫學院附設醫院 | 102/09/18 | 550000.0 | 是 |